--- a
+++ b/clusters/9knumclustersv2/clust_111.txt
@@ -0,0 +1,91 @@
+For patients who undergo mastectomy, the margins must be histologically free of residual (microscopic or gross) tumor
+Per the operative report, the gross total resection of the primary tumor with curative intent was completed within  weeks prior to randomization
+Patients with gross total resection of the primary tumor prior to enrollment on ARST are NOT eligible; patients who have experienced tumor recurrence after a gross total tumor resection are NOT eligible
+Primary surgical debulking before protocol therapy is permissible; this would include removal of gross symptomatic disease in the pelvis and/or vagina\r\n* Exenterative surgery is not permissible; patients with complete resection of gross recurrent disease are eligible
+Patients who have gross residual disease or distant metastatic disease
+Gross total resection (GTR) will be interpreted as modified Simpson grade - without gross residual dural-based or extradural tumor; GTR must be confirmed both by modified Simpson grade and by post-operative magnetic resonance imaging (MRI) findings
+Status post gross total resection with curative intent
+Any evidence of hematemesis, melena, hematochezia, ? grade  hemoptysis, or gross hematuria
+Surgery achieves either no gross residual disease (R) or optimal cytoreductive status defined as no single lesion measuring more than . mm in its greatest diameter
+Patients who undergo surgical resection will be allowed regardless of human papilloma virus (HPV) status provided they have one of the following criteria: \r\n* Positive margins on pathology\r\n* Evidence of extracapsular spread on nodal pathology\r\n* Gross residual disease on postoperative or simulation imaging\r\n* N/ disease\r\n* T/ disease\r\n* Multifocal perineural invasion and/or lymphovascular space invasion
+The only surgical consideration is biopsy. Subjects who had gross total resection, partial resection and/or debulking are excluded.
+Subjects who had gross total tumor resection, partial resection, and/or debulking surgery.
+Participant has symptoms of gross hematuria or gross hemoptysis
+Patients must have received no previous therapy for the tumor with the exception of corticosteroids and surgery; patients with a gross total resection will not be eligible
+Gross total surgical resection with curative intent of the primary tumor and at least unilateral neck dissection within  weeks of registration
+Have evidence of active clinically significant bleed (e.g., gastrointestinal bleed, hemoptysis, or gross hematuria) at screening
+Uncontrolled cystitis, significant bladder pain or spasms, or gross hematuria that in the opinion of the treating investigator, should preclude study entry
+Patients who have undergone a gross total resection for recurrence will be eligible, and MLA will be directed at treating a peritumoral margin of .- cm surrounding the resection cavity to disrupt the blood brain barrier (BBB) and potentially increase access of MK- to the peritumoral infiltrating glioma cells
+Must have undergone gross total resection of the primary tumor with curative intent within the past  weeks with surgical pathology demonstrating >=  of the following criteria for \intermediate\ risk of recurrence:\r\n* Perineural invasion\r\n* Lymphovascular invasion\r\n* Single lymph node >  cm or at least  nodes without evidence of extracapsular extension\r\n* Close margins defined as <  mm but not frankly positive (in the case of ambiguous, controversial, or superseded margins, final clinical assessment regarding margin status will prevail)\r\n* Pathologically confirmed T or T primary tumor.
+The primary tumor must be considered resectable by RP with gross negative margins as determined by a urologist. (Applicable to cohorts A and B only)
+On-going gross hematuria associated with clots
+Gross total excision of both the primary and nodal disease
+The patient must be a candidate for surgical debulking (either subtotal or gross total resection); biopsy-only candidates will not be eligible
+Patients must have undergone gross total surgical resection within  days prior to registration and beginning of therapy under the clinical trial. Note: Patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection.
+Presence of metastatic disease or gross orbital involvement
+No evidence of gross hematuria
+Gross (visible) hematuria
+Gross disease within the breast must be unifocal; (patients with microscopic multifocality are eligible as long as the total extent of tumor, gross and microscopic, occupies a volume with greatest dimension  cm or less)
+Macroscopic complete salvage surgery with curative intent (surgery was not performed only for biopsy or palliation); final pathology and imaging must indicate a R or R resection (no gross disease remaining)
+Any patient with gross residual disease following salvage surgery
+Patients with gross residual tumor after surgical resection
+COHORT II: Gross disease must be unifocal on Mammo/ MRI imaging
+Current evidence of hematemesis, melena or gross hematuria
+No gross vascular invasion or regional nodal or distant metastases
+Presence of metastatic disease or gross (residual) orbital involvement
+Patients will have no evidence of gross vascular invasion
+The presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Pagets disease is permitted
+Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or re-resection will be permitted.
+Prior craniotomy and gross total or sub-total resection of tumor at this recurrence
+Gross total or partial tumor resection is not possible or not planned
+Patients with gross total resection of the primary tumor prior to enrollment are not eligible; patients who have experienced tumor recurrence after gross total tumor resection are not eligible
+Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p negative), larynx, or hypopharynx squamous cell carcinoma (SCC) within  days prior to registration; note: patients may have a biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within  days prior to registration; if, however, patients have ablative resection but demonstrate rapid gross recurrence or are determined to have gross persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
+Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p negative), larynx, or hypopharynx within  days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within  days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
+Candidate for gross total or subtotal resection
+Gross total excision of both primary and nodal disease with curative intent; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease; in other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed
+Previous radiosurgery to any currently progressive gross metastatic disease
+Patients with multiple regional nodal basin involvement are eligible; gross or microscopic extracapsular nodal extension is permitted
+Positive surgical margins are permitted if the surgeon confirms complete resection of gross metastatic disease, and post-operative scans are negative
+Total (aggregate) gross tumor volume >  cm^ ( ccs or . liters)
+Active untreated gross hematuria for any cause
+Patients with gross residual or metastatic tumor findings following complete surgical treatment for uterine LMS
+Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy; patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible\r\n* The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved; the pathology report must include documentation of the margin status and the size of the tumor; the pathology report must also include the status of the three major marginsbile duct, pancreatic parenchyma, and retroperitoneal (uncinate)
+Resected tumor: No evidence of gross tumor at the surgical resection margin noted in the final surgery report. No evidence of gross residual adenopathy
+Patients who have had gross total excision of the primary tumor.
+Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or re-resection will be permitted
+The tumor must be unifocal, confined to the supratentorial compartment and have undergone a gross total or near gross total resection; this will increase the likelihood that the patient will not require corticosteroids or develop pseudoprogression
+Patients must have had all gross disease resected (R or R resection)
+Not undergoing surgical resection or for whom gross total resection is not possible
+Patient should have surgery (biopsy, partial resection or gross total resection) and no additional anti-cancer therapy except the chemoradiation as specified in the protocol
+Achieved a gross total or sub-total resection at time of surgery
+Gross residual tumor or positive margins after surgery that is un-excised, as radiation dose in the study will be limited to  Gy.
+Gross total surgical resection with curative intent of the primary tumor and at least unilateral neck dissection within  weeks of registration
+Evidence of clinically evident gross residual or recurrent disease following preoperative therapy and surgery
+The patient must have undergone surgical resection (gross total, subtotal, or biopsy) of the spinal lesion(s) no more than  weeks prior to SRS treatment
+Patient must not have gross residual and/or microscopic disease present after surgery including re-resection(s), per the operative and pathology report
+Participants with gross hematuria are not eligible; patients with microscopic hematuria are eligible
+Participants with gross hematuria are ineligible
+Patients with more than  (i.e.,  or greater) uncontrolled or untreated extracranial sites of gross disease
+Gross extension of tumor into the lumen of the duodenum
+Subjects must have undergone primary gross total resection (no re-resected patients are allowed) with fulfillment of at least  of the following histologic criteria for high-risk disease:
+Close (<mm) or positive surgical margins on microscopic evaluation with no gross residual tumor
+Participants may have had a gross total resection, sub-total resection or biopsy\r\nonly
+Patients who have undergone gross total resection and have no detectable residual disease are eligible
+Gross total resection as determined by the intraoperative observations of the neurosurgeon of record and confirmed by postoperative MR imaging; gross total resection is defined as residual tumor or imaging abnormality (not definitive for residual tumor) whose size is <  cm^ on postoperative computed tomography (CT) or MR images
+Histologic diagnosis of nodular desmoplastic medulloblastoma with less than gross total resection, but with no evidence of metastasis
+Prior cancer treatment for this cancer, including gross total tumor excision
+Concurrent febrile illness, urinary tract infection, or gross hematuria
+Gross total resection followed by conventional chemoradiation therapy without progression of disease.
+Patients with gross disease involving only the posterior elements
+Patients with both pedicles involved with gross disease at the level of potential cement augmentation
+Symptoms of gross hematuria or gross hemoptysis.
+Patients with clinical evidence of gross disease
+Gross nodal or metastatic disease at presentation (>= N, M)
+The presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Paget's disease is permitted
+Patients with gross tumor involvement of the oral cavity or oral mucosa
+Breast-conserving surgery with surgical excision of all gross disease with negative surgical margins (with the exception of a positive margin at skin and/or fascia where no more breast tissue can be removed) or mastectomy surgery with no gross residual disease
+No gross disease visible on imaging at the start of radiotherapy
+Definitive/gross total lesion resection
+No gross disease visible on imaging at the start of radiotherapy
+Subtotal, gross total or biopsy patients will be eligible
+Gross tumor volume (GTV) or resection cavity must be visible on CT such that it can be delineated as a target for radiotherapy